| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
38,180,000 |
| Market
Cap: |
56.51(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$1.48 - $1.98 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile TCR2 Therapeutics is a clinical-stage cell therapy company developing T cell therapies for cancer patients suffering from solid tumors by powering the T cell receptor (TCR) with its TCR Fusion Construct T cells (TRuC-T cells). Co.'s TRuC-T cells recognize and kill cancer cells by using the entire TCR signaling complex. Co.'s TRuC-T cell targeting mesothelin-expressing solid tumors are: gavocabtagene autoleucel, in which Co. is conducting its clinical trial to treat patients with non-small cell lung cancer, ovarian cancer, malignant pleural/peritoneal mesothelioma or cholangiocarcinoma; and TC-510, which incorporates a PD-1:CD28 chimeric switch receptor.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
468,513 |
468,513 |
| Total Buy Value |
$0 |
$0 |
$885,368 |
$885,368 |
| Total People Bought |
0 |
0 |
1 |
1 |
| Total Buy Transactions |
0 |
0 |
9 |
9 |
| Total Shares Sold |
0 |
0 |
140,340 |
287,401 |
| Total Sell Value |
$0 |
$0 |
$263,840 |
$445,404 |
| Total People Sold |
0 |
0 |
2 |
6 |
| Total Sell Transactions |
0 |
0 |
2 |
33 |
| End Date |
2024-01-25 |
2023-10-24 |
2023-04-25 |
2022-04-25 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Tang Capital Partners Lp |
10% Owner |
– – • |
2023-06-01 |
4 |
D |
$0.00 |
$0 |
I/I |
(4,394,800) |
0 |
|
- |
|
| Mpm Asset Management Llc |
10% Owner |
– – • |
2023-06-01 |
4 |
D |
$0.00 |
$0 |
I/I |
(4,158,964) |
0 |
|
- |
|
| Mpm Oncology Impact Management Lp |
10% Owner |
– – • |
2023-06-01 |
4 |
D |
$0.00 |
$0 |
D/D |
(3,370,982) |
0 |
|
- |
|
| Mpm Sunstates Gp Managing Member Llc |
10% Owner |
– – • |
2023-06-01 |
4 |
D |
$0.00 |
$0 |
I/I |
(4,158,964) |
0 |
|
- |
|
| Gadicke Ansbert |
Director |
– • • |
2023-06-01 |
4 |
D |
$0.00 |
$0 |
I/I |
(7,529,946) |
0 |
|
- |
|
| Menzel Garry E |
President and CEO |
• • – |
2023-06-01 |
4 |
D |
$0.00 |
$0 |
D/D |
(138,871) |
0 |
|
- |
|
| Menzel Garry E |
President and CEO |
• • – |
2023-06-01 |
4 |
D |
$0.00 |
$0 |
I/I |
(265,459) |
0 |
|
- |
|
| Olagunju Peter |
Chief Operating Officer |
• – – |
2023-06-01 |
4 |
D |
$0.00 |
$0 |
D/D |
(24,092) |
0 |
|
- |
|
| Justice Angela |
Chief People Officer |
• – – |
2023-06-01 |
4 |
D |
$0.00 |
$0 |
D/D |
(48,745) |
0 |
|
- |
|
| Cardama Alfonso Quintas |
Chief Medical Officer |
• – – |
2023-06-01 |
4 |
D |
$0.00 |
$0 |
D/D |
(109,459) |
0 |
|
- |
|
| Tang Capital Partners Lp |
10% Owner |
– – • |
2023-05-25 |
4 |
B |
$1.72 |
$86,000 |
I/I |
50,000 |
4,394,800 |
1.5 |
-15% |
|
| Evnin Luke |
10% Owner |
– – • |
2023-05-22 |
4 |
S |
$1.88 |
$131,920 |
D/D |
(70,170) |
304,001 |
|
19% |
|
| Evnin Luke |
10% Owner |
– – • |
2023-05-22 |
4 |
OE |
$0.74 |
$131,919 |
D/D |
178,269 |
374,171 |
|
- |
|
| Gadicke Ansbert |
Director |
– • • |
2023-05-22 |
4 |
S |
$1.88 |
$131,920 |
I/I |
(70,170) |
304,001 |
|
19% |
|
| Gadicke Ansbert |
Director |
– • • |
2023-05-22 |
4 |
OE |
$0.74 |
$131,919 |
I/I |
178,269 |
374,171 |
|
- |
|
| Tang Capital Partners Lp |
10% Owner |
– – • |
2023-05-12 |
4 |
B |
$1.95 |
$12,057 |
I/I |
6,183 |
4,344,800 |
1.5 |
-24% |
|
| Tang Capital Partners Lp |
10% Owner |
– – • |
2023-05-11 |
4 |
B |
$1.95 |
$75,592 |
I/I |
38,765 |
4,338,617 |
1.5 |
-24% |
|
| Tang Capital Partners Lp |
10% Owner |
– – • |
2023-05-10 |
4 |
B |
$1.95 |
$13,209 |
I/I |
6,774 |
4,299,852 |
1.5 |
-25% |
|
| Tang Capital Partners Lp |
10% Owner |
– – • |
2023-05-09 |
4 |
B |
$1.95 |
$39,275 |
I/I |
20,141 |
4,293,078 |
1.5 |
-25% |
|
| Tang Capital Partners Lp |
10% Owner |
– – • |
2023-05-08 |
4 |
B |
$1.95 |
$111,292 |
I/I |
57,073 |
4,272,937 |
1.5 |
-24% |
|
| Tang Capital Partners Lp |
10% Owner |
– – • |
2023-05-05 |
4 |
B |
$1.90 |
$319,806 |
I/I |
166,823 |
4,215,864 |
1.5 |
-24% |
|
| Tang Capital Partners Lp |
10% Owner |
– – • |
2023-05-04 |
4 |
B |
$1.86 |
$193,888 |
I/I |
104,241 |
4,049,041 |
1.5 |
-21% |
|
| Tang Capital Partners Lp |
10% Owner |
– – • |
2023-05-03 |
4 |
B |
$1.85 |
$34,249 |
I/I |
18,513 |
3,944,800 |
1.5 |
-19% |
|
| Olagunju Peter |
Chief Technical Officer |
• – – |
2022-12-13 |
4 |
AS |
$1.07 |
$1,767 |
D/D |
(1,659) |
24,092 |
|
77% |
|
| Cardama Alfonso Quintas |
Chief Medical Officer |
• – – |
2022-12-13 |
4 |
AS |
$1.06 |
$5,042 |
D/D |
(4,752) |
109,459 |
|
77% |
|
132 Records found
|
|
Page 1 of 6 |
|
|
